OakChart

Tscan Therapeutics Inc

TCRXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:31 PM ET

0.1845-0.0007 (-0.38%)
2026-11-11 21:34 CET
Market cap
12.55 USD m
Revenue, TTM
7.11 USD m
Net income, TTM
-117.71 USD m
Free cash flow, TTM
-118.44 USD m
EPS diluted, TTM
-0.91
P/E
-
Compare

Price

TCRX against its 20, 50 and 200-day averages
2050200beat
0.501.004.3M8.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TCRXclose 0.1820-day 0.2050-day 0.27200-day 0.810.18

87.5% under the 52-week high of 1.47 on 20 Apr 2026. 52-week low 0.17 on 5 Nov 2026. Last 15 sessions, 32.7% high to low

Volume 0.34× normal · the line is the 50-bar volume average

Profile

TCRX
52-week range, 1% of the way up
0.171.47

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Waltham, MA.

Employees142
IPOJul 16, 2021
Beta1.18
ATR, 14d0.02
Rel volume0.34
Short float3.79%
Insider own21.33%
Inst own50.56%

Snapshot

6 groups

Valuation

Index-
Market Cap12.50M
Enterprise Value3.23M
Income-117.71M
Sales7.11M
Book/sh1.02
Cash/sh1.48
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees142
IPOJul 16, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S1.76
P/B0.18
P/C0.12
P/FCF-
EV/EBITDA-
EV/Sales0.45
Quick Ratio3.37
Current Ratio3.37
Debt/Eq1.32
LT Debt/Eq1.04
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.91
EPS next Y-0.60
EPS next Q-0.19
EPS this Y20.44%
EPS next Y24.57%
EPS next 5Y16.60%
EPS past 3/5Y28.66% 2.08%
Sales past 3/5Y-8.63% 56.92%
EPS Y/Y TTM17.34%
Sales Y/Y TTM2.15%
EPS Q/Q17.98%
Sales Q/Q-65.83%
EarningsAug 12 BMO
EPS/Sales Surpr.9.23% -43.95%

Ownership

Insider Own21.33%
Insider Trans0.00%
Inst Own50.56%
Inst Trans30.64%
ROA-50.09%
ROE-95.80%
ROIC-83.79%
Gross Margin59.47%
Oper. Margin-1695.15%
Profit Margin-1655.35%
SMA20-7.69%
SMA50-31.08%
SMA200-77.31%
Trades-

Technical

Shs Outstand63.50M
Shs Float53.32M
Short Float3.79%
Short Ratio2.71
Short Interest2.02M
52W High1.47 -87.45%
52W Low0.17 7.86%
Volatility12.44% 10.80%
ATR (14)0.02
RSI (14)35.82
Beta1.18
Rel Volume0.34
Avg Volume746.39K
Volume240,904

Performance

Perf Week-12.14%
Perf Month-14.86%
Perf Quarter-76.10%
Perf Half Y-84.09%
Perf YTD-81.55%
Perf Year-84.88%
Perf 3Y-95.88%
Perf 5Y-97.88%
Perf 10Y-
Recom2.60
Target Price2.67
Prev Close0.19
Price0.18
Change %-0.38%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Sep 08, 2026DowngradeHH.C. WainwrightBuy → Neutral$1+442.0%
Nov 14, 2025DowngradeMMorgan StanleyOverweight → Equal-Weight
May 16, 2024InitiatedBBTIG ResearchBuy$12+6,404.1%
May 13, 2024InitiatedNNeedhamBuy$11+5,862.1%
Jun 22, 2023InitiatedWWedbushOutperform$8+4,236.0%

Peers

Mkt cap
TickerCompanyMkt cap
MRKRMarker Therapeutics Inc15.95M
IMTXImmatics N.V1.01B
ESLAEstrella Immunopharma Inc33.12M
ATRAAtara Biotherapeutics Inc82.01M
ACETAdicet Bio Inc27.71M
IMCRImmunocore Holdings plc ADR1.64B
CRBUCaribou Biosciences Inc42.15M
LYELLyell Immunopharma Inc411.56M
ALLOAllogene Therapeutics Inc312.48M
IOVAIovance Biotherapeutics Inc3.76B

Insider trading

3 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lynx1 Capital Management LP10% OwnerDec 19 '25Buy0.9080,06971,9747,937,416Dec 23 06:17 PM
Lynx1 Capital Management LP10% OwnerDec 22 '25Buy0.9075,50067,9508,012,916Dec 23 06:17 PM
Lynx1 Capital Management LP10% OwnerDec 23 '25Buy0.906,2325,6028,019,148Dec 23 06:17 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • Ionis rare neurology drug approved; Pfizer inks an ADC deal (BioPharma Dive) +5.55%
  • TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program (InvestorsHub) -42.80%
  • TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors (GlobeNewswire)
  • TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Cell and gene therapy manufacturers turn to specialist automation partners (Pharmaceutical Technology)
  • TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies (GlobeNewswire)
  • TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (GlobeNewswire)
  • TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation (GlobeNewswire) -5.97%
  • Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies (Business Wire)
  • TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting (GlobeNewswire)
  • TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
  • TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
  • TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.230-0.253-0.2301.051.885
2026Q12026-05-06-0.220-0.203-0.2210.982.505
2025Q42026-03-04-0.180-0.270-0.1772.572.446
2025Q32025-11-12-0.280-0.334-0.2752.511.987
2025Q22025-08-12-0.280-0.327-0.2853.081.317
2025Q12025-05-06-0.260-0.292-0.2632.171.096
2024Q42025-03-05-0.300-0.319-0.2970.671.528
2024Q32024-11-12-0.250-0.315-0.2521.051.178
2024Q22024-08-12-0.280-0.283-0.2790.541.807
2024Q12024-05-13-0.320-0.259-0.3180.603.985
2023Q42024-03-06-0.210-0.289-0.4107.213.456
2023Q32023-11-09-0.240-0.453-0.2433.894.455
2023Q22023-08-10-0.510-0.765-0.5093.154.374
2023Q12023-05-10-0.930-0.693-0.9316.804.874
2022Q42023-03-08-0.780-0.724-0.7733.104.105
2022Q32022-11-09-0.670-0.726-0.6753.363.935

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-4.170-6.392-4.16910.1411.32
2022FY-2.750-2.760-2.75413.5413.89
2023FY-1.360-1.542-1.36021.0516.86
2024FY-1.140-1.273-1.1392.823.61
2025FY-1.000-1.215-1.00010.3311.15
2026FY--0.796--2.91
2027FY--0.600--1.25
2028FY--0.580--11.84
2029FY--0.553--31.87
2030FY--0.413--78.70

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-044030.460.001.25
2026Q3S2026-09-014021.080.002.50
2026Q3S2026-08-124011.450.002.50
2026Q3S2026-05-064001.750.002.50
2026Q3S2026-03-044001.750.002.50
2026Q3S2026-01-264001.750.002.50
2026Q3S2025-11-124101.750.002.50
2026Q3S2025-11-113011.290.002.00
2026Q3S2025-11-103011.290.002.00
2026Q3S2025-11-093011.290.002.00
2026Q3S2025-11-083011.290.002.00
2026Q3S2025-11-073011.290.002.00
2026Q3S2025-11-063011.290.002.00
2026Q3S2025-11-053011.290.002.00

Estimate history

EPS, annual-0.581-1.111-4.169-2.754-1.36-1.139-1-0.9062
Period2019202020212022202320242025TTM
EPS, quarterly-0.279-0.252-0.297-0.263-0.285-0.275-0.177-0.221-0.234
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual01.08510.14113.53521.0492.81610.3257.11
Period2019202020212022202320242025TTM
Sales, quarterly0.5361.0490.6652.1713.0762.5112.5670.9821.051
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual23.52223.52223.90824.22647.8356.59156.90267.779
Period2019202020212022202320242025MRQ
Shares, quarterly52.93353.35456.59156.59156.74856.74856.90260.10167.779
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue7.1110.322.8221.0513.5410.141.080.00
Cost of Goods Sold Incl. D&A2.882.874.115.365.143.33-0.52
Gross Profit4.237.46-1.2915.698.406.81--0.52
Selling, General and Administrative Excl. Other124.77143.27133.53109.1575.0355.4526.0913.69
Research and Development94.62111.94103.9788.1559.8244.9520.589.44
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-120.54-135.81-134.82-93.46-66.64-48.64-26.23-14.21
Interest Expense2.792.773.653.761.180.000.000.00
Unusual Expense0.000.001.090.000.000.000.000.00
Net Income Before Taxes-117.71-129.77-127.50-89.22-66.22-48.62-26.13-13.66
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-117.71-129.77-127.50-89.22-66.22-48.62-26.13-13.66
Net Income From Continuing Operations-117.71-129.77-127.50-89.22-66.22-48.62-26.13-13.66
Net Income-117.71-129.77-127.50-89.22-66.22-48.62-26.13-13.66
EPS (Recurring)-0.91-1.00-1.13-1.36-2.75-4.17-1.11-0.58
EPS (Basic, Before Extraordinaries)-0.91-1.00-1.14-1.36-2.75-4.17-1.11-0.58
EPS (Diluted)-0.91-1.00-1.14-1.36-2.75-4.17-1.11-0.58
EBITDA-117.66-132.95-130.71-88.10-61.50-45.31-25.00-13.69
Non-Operating Income (Expense)5.628.8212.068.001.590.020.110.55
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense17.0011.719.555.214.552.520.380.18
Price To Sales Ratio17.9112.57120.9018.172.755.18--
Gross Margin59.4772.24-45.8874.5362.0567.18--
Operating Margin-1,695.15-1,315.38-4,787.68-444.00-492.32-479.65-2,417.79-
Net Margin-1,655.35-1,256.81-4,527.66-423.86-489.26-479.49-2,408.02-
Shares Outstanding67.7856.9056.5947.8324.2323.9123.5223.52
Market Capitalization12.5512.55162.25253.8929.3583.8189.96-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.050.982.572.513.082.170.671.05
Cost of Goods Sold Incl. D&A0.700.690.720.770.700.680.711.03
Gross Profit0.350.291.841.742.381.49-0.050.02
Selling, General and Administrative Excl. Other30.8429.4325.7038.8041.0337.7436.6732.64
Research and Development22.7921.3019.4431.1032.1129.2929.3526.26
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-30.49-29.14-23.86-37.05-38.65-36.25-36.71-32.62
Interest Expense0.700.690.700.700.690.680.780.96
Unusual Expense0.000.000.000.000.000.001.090.00
Net Income Before Taxes-30.36-28.67-22.98-35.71-36.95-34.13-35.81-29.89
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-30.36-28.67-22.98-35.71-36.95-34.13-35.81-29.89
Net Income From Continuing Operations-30.36-28.67-22.98-35.71-36.95-34.13-35.81-29.89
Net Income-30.36-28.67-22.98-35.71-36.95-34.13-35.81-29.89
EPS (Recurring)-0.23-0.22-0.18-0.28-0.28-0.26-0.29-0.25
EPS (Basic, Before Extraordinaries)-0.23-0.22-0.18-0.28-0.28-0.26-0.30-0.25
EPS (Diluted)-0.23-0.22-0.18-0.28-0.28-0.26-0.30-0.25
EBITDA-29.79-28.45-23.14-36.28-37.96-35.57-36.00-31.59
Non-Operating Income (Expense)0.831.161.582.042.392.802.783.69
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.512.462.013.013.273.412.712.52
Price To Sales Ratio17.9114.3612.5828.0527.0240.48130.4063.14
Gross Margin33.4929.4371.8369.4577.3468.77-6.922.10
Operating Margin-2,901.33-2,967.31-929.41-1,475.59-1,256.60-1,669.74-5,520.60-3,109.82
Net Margin-2,888.58-2,919.14-895.09-1,422.14-1,201.30-1,571.95-5,384.81-2,849.09
Shares Outstanding67.7860.1056.9056.7556.7556.5956.5953.35
Market Capitalization12.5557.4756.75103.2882.0678.09162.25263.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments152.41290.11192.04120.03161.4134.7941.76
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets4.802.612.194.104.251.650.61
Total Current Assets157.21292.72194.24124.13165.6536.4542.38
Net Property, Plant & Equipment66.4571.6071.2369.2017.2612.536.41
Total Investments and Advances5.035.035.035.045.200.760.59
Intangible Assets0.000.000.000.000.000.000.00
Deferred Tax Assets15.78------
Other Assets0.101.771.650.720.000.000.00
Total Assets244.56371.12272.15199.09188.1149.7449.38
Short Term Debt Incl. Current Port. of LT Debt7.174.576.593.681.651.420.44
Accounts Payable1.244.282.372.911.762.911.01
Other Current Liabilities10.2927.1120.8510.7117.9313.120.94
Total Current Liabilities18.7035.9629.8217.3021.3417.452.40
Long Term Debt86.9792.8185.8482.304.396.024.44
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities15.78------
Other Liabilities0.001.385.620.051.599.050.00
Total Liabilities121.44130.15121.2899.6627.3332.526.84
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0059.6859.68
Common Equity123.12240.97150.8799.43160.78-42.46-17.14
Total Shareholders Equity123.12240.97150.8799.43160.7817.2242.54
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity123.12240.97150.8799.43160.7817.2242.54
Total Liabilities & Stockholders Equity244.56371.12272.15199.09188.1149.7449.38
Book Value Per Share2.164.263.154.106.72-1.81-0.73
Tangible Book Value Per Share2.164.263.154.106.72-1.81-0.73
Full-Time Employees14219415413710557-
Price to Book Ratio0.180.711.650.320.670.66-
Return on Assets-42.15-39.64-37.87-34.21-40.89-52.72-
Return on Equity-71.28-65.08-71.29-50.90-54.64-87.44-
Return on Invested Capital-61.77-38.20-37.69-36.44-29.44-112.43-29.07
Quick Ratio8.418.146.517.177.762.0917.69
Current Ratio8.418.146.517.177.762.0917.69

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-117.71-129.77-127.50-89.22-66.22-48.62-26.13-13.66
Depreciation2.882.874.115.365.143.331.230.52
Other Funds (Non Cash)10.089.167.514.894.812.520.520.32
Funds from Operations-104.75-117.74-115.88-78.96-56.27-42.78-24.38-12.82
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-11.53-18.185.0517.61-10.23-5.9021.360.30
Cash from Operating Activities-116.28-135.92-110.82-61.36-66.50-48.68-3.02-12.52
Capital Expenditures-2.16-4.41-3.83-3.15-4.22-9.94-4.24-1.25
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.030.000.000.000.000.000.000.00
Purchase or Sale of Investments49.00113.78-48.79-57.610.000.000.000.00
Purchase of Investments0.00-87.47-241.44-77.610.000.000.000.00
Sale Or Maturity of Investments49.00201.25192.6620.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities46.87109.37-52.61-60.76-4.22-9.94-4.24-1.25
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock0.170.26193.45135.440.33189.670.2934.81
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.170.26193.45135.440.33189.670.2934.81
Proceedsfrom Stock Options0.000.00158.2792.320.00189.380.0034.81
Issuance or Reduction of Debt, Net0.000.0015.310.0029.030.000.000.00
Change in Long Term Debt0.000.0015.310.0029.030.000.000.00
Issuance of Long Term Debt0.000.0032.460.0029.030.000.000.00
Reduction of Long Term Debt0.000.00-17.140.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities0.170.26208.76135.4429.36189.670.2934.81
Net Change in Cash-69.24-26.2845.3313.33-41.37131.05-6.9721.04
Free Cash Flow-118.44-140.33-114.65-64.50-70.73-58.62-7.26-13.77
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments100.16128.06152.41184.45218.04251.69
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.254.714.803.713.083.15
Total Current Assets104.40132.77157.21188.16221.13254.84
Net Property, Plant & Equipment61.9764.1366.4568.7470.6271.09
Total Investments and Advances5.035.035.035.035.035.03
Intangible Assets0.000.000.000.000.000.00
Other Assets0.050.070.100.291.781.75
Total Assets171.45201.99228.79262.23298.56332.71
Short Term Debt Incl. Current Port. of LT Debt19.427.447.176.906.294.97
Accounts Payable3.122.301.246.354.544.97
Other Current Liabilities8.4210.2310.2915.9520.5019.88
Total Current Liabilities30.9619.9718.7029.2131.3229.82
Long Term Debt71.4785.1086.9788.7290.4192.07
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.280.110.62
Total Liabilities102.43105.07105.67118.20121.85122.51
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity69.0296.92123.12144.02176.71210.20
Total Shareholders Equity69.0296.92123.12144.02176.71210.20
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity69.0296.92123.12144.02176.71210.20
Total Liabilities & Stockholders Equity171.45201.99228.79262.23298.56332.71
Book Value Per Share1.021.612.162.543.113.71
Tangible Book Value Per Share1.021.612.162.543.113.71
Full-Time Employees138139142-210-
Price to Book Ratio0.180.470.390.580.390.32
Return on Assets-50.09-46.50-43.26-46.73-40.62-45.85
Return on Equity-95.80-80.95-71.28-76.44-63.33-78.93
Return on Invested Capital-21.61-15.75-10.94-15.34-13.83-11.29
Quick Ratio3.376.658.416.447.068.55
Current Ratio3.376.658.416.447.068.55

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-30.36-28.67-22.98-35.71-36.95-34.13
Depreciation0.700.690.720.770.700.68
Other Funds (Non Cash)2.582.582.072.842.132.12
Funds from Operations-27.08-25.39-20.18-32.10-34.13-31.33
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.461.11-11.82-0.360.39-6.38
Cash from Operating Activities-27.54-24.28-32.00-32.46-33.74-37.71
Capital Expenditures-0.49-0.07-0.17-1.43-1.28-1.53
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.030.000.000.000.000.00
Purchase or Sale of Investments0.000.0015.0034.0049.7215.06
Purchase of Investments0.000.000.000.00-26.53-60.94
Sale Or Maturity of Investments0.000.0015.0034.0076.2576.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.47-0.0714.8332.5848.4413.53
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.100.000.070.000.190.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.100.000.070.000.190.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.100.000.070.000.59-0.40
Net Change in Cash-27.90-24.35-17.100.1115.29-24.58
Free Cash Flow-28.03-24.35-32.17-33.89-35.02-39.24

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 2.82M 2025: 10.33M
United States2024: 2.82M 2025: 10.33M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.79%2.0M53.3M731.09K
2026-10-154.27%2.3M53.3M757.28K
2026-09-304.66%2.5M53.3M835.62K
2026-09-153.93%2.3M58.1M841.44K
2026-08-313.02%1.7M57.9M587.20K
2026-08-142.77%1.6M57.9M631.28K
2026-07-312.78%1.6M56.1M704.74K
2026-07-152.47%1.4M56.1M803.00K
2026-06-301.26%0.7M56.1M859.25K
2026-06-151.36%0.8M56.1M810.76K
2026-05-291.68%0.9M55.6M866.90K
2026-05-151.58%0.9M55.6M866.74K
2026-04-301.57%0.9M55.3M805.72K
2026-04-151.98%0.9M47.7M699.05K
2026-03-313.96%1.9M47.6M531.03K
2026-03-133.97%1.9M47.6M554.12K
2026-02-274.05%1.9M47.6M569.95K
2026-02-134.22%2.0M47.5M628.86K
2026-01-305.53%2.6M46.4M766.65K
2026-01-155.08%2.4M46.4M783.05K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-26DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-20SEC
2026-10-16PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-20SEC
2026-10-168-KCurrent report2026-10-13SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-308-KCurrent report2026-09-24SEC
2026-09-25SCHEDULE 13GSEC
2026-09-118-KCurrent report2026-09-08SEC
2026-09-028-KCurrent report2026-08-27SEC
2026-08-188-KCurrent report2026-08-12SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-06-228-KCurrent report2026-06-22SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-228-KCurrent report2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-224Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-068-KCurrent report2026-05-06SEC
2026-04-17ARSAnnual report to security holders. 2025-12-31SEC
2026-04-17DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-20SEC
2026-04-07PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-20SEC
2026-04-028-KCurrent report2026-03-31SEC
2026-03-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12145.53K300
2025-110000

Institutional holders

Manager% owned
Lynx1 Capital Management LP12.27%
BVF INC/IL8.51%
BAKER BROS. ADVISORS LP4.26%
VANGUARD CAPITAL MANAGEMENT LLC3.30%
TWO SIGMA INVESTMENTS, LP2.98%
ACADIAN ASSET MANAGEMENT LLC2.50%
RENAISSANCE TECHNOLOGIES LLC2.03%
Deer Management Co. LLC1.91%
MILLENNIUM MANAGEMENT LLC1.78%
JACOBS LEVY EQUITY MANAGEMENT, INC1.61%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.30%
VANGUARD EXTENDED MARKET INDEX FUND0.88%
BlackRock Health Sciences Term Trust0.62%
Fidelity Extended Market Index Fund0.49%
iShares Micro-Cap ETF0.26%
Fidelity Total Market Index Fund0.13%
Ultra-Small Company Market Fund0.11%
Fidelity Series Total Market Index Fund0.11%
SMALL CAP EQUITY FUND0.10%
Multi-Manager Small Cap Equity Strategies Fund0.10%

OakChart. TCRX. Cached 15 minutes.